{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=timolol+ophthalmic+solution",
    "query": {
      "intervention": "timolol ophthalmic solution"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=timolol+ophthalmic+solution&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T23:05:28.773Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00811850",
      "title": "Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-12",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811850"
    },
    {
      "nct_id": "NCT03323164",
      "title": "Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma; Drugs",
        "Normal Tension Glaucoma",
        "Primary Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Timolol Maleate",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 35,
      "start_date": "2017-07-10",
      "completion_date": "2020-05-30",
      "has_results": true,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03323164"
    },
    {
      "nct_id": "NCT02207621",
      "title": "Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02% BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 756,
      "start_date": "2014-07",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207621"
    },
    {
      "nct_id": "NCT01170884",
      "title": "Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2009-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170884"
    },
    {
      "nct_id": "NCT02250612",
      "title": "SYL040012, Treatment for Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "1 drop of 0.375% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 0.750% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 1.125% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 1.5% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 0.5 % timolol maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sylentis, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2014-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 4,
      "location_summary": "Artesia, California • Petaluma, California • Morrow, Georgia + 1 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02250612"
    },
    {
      "nct_id": "NCT05114239",
      "title": "Topical Timolol: a Comparison of Surgical Outcomes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wound Heal"
      ],
      "interventions": [
        {
          "name": "Timolol 0.25% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Standard Wound Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Keith G. LeBlanc, Jr, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-04-07",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Metairie, Louisiana",
      "locations": [
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05114239"
    },
    {
      "nct_id": "NCT04149899",
      "title": "Safety and IOP-Lowering Effects of WB007",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Primary Open Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "WB007 0.05%",
          "type": "DRUG"
        },
        {
          "name": "WB007 0.15%",
          "type": "DRUG"
        },
        {
          "name": "WB007 0.4%",
          "type": "DRUG"
        },
        {
          "name": "Timolol 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2019-11-14",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-27",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04149899"
    },
    {
      "nct_id": "NCT01177098",
      "title": "Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost /timolol formulation A fixed combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost/timolol fixed combination ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 561,
      "start_date": "2010-10",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2013-03-29",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177098"
    },
    {
      "nct_id": "NCT02097719",
      "title": "Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost 0.01%",
          "type": "DRUG"
        },
        {
          "name": "travoprost 0.004%",
          "type": "DRUG"
        },
        {
          "name": "timolol 0.5%",
          "type": "DRUG"
        },
        {
          "name": "hypromellose 0.3%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2014-05",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "Racine, Wisconsin",
      "locations": [
        {
          "city": "Racine",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02097719"
    },
    {
      "nct_id": "NCT01707381",
      "title": "BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "BOL-303259-X",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 25,
      "start_date": "2012-11",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2018-09-04",
      "last_synced_at": "2026-09-09T23:05:28.773Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01707381"
    }
  ]
}